Here's what's quietly reshaping trade flows between India and Switzerland: specialty organic chemicals worth $232.5 million in 2025, with India controlling 71% of the Swiss market for these compounds. That's not just a number — it's the second-largest export corridor between the two nations, trailing only food and agricultural goods at $101.7 million. The gap is closing. (See also: amino-naphthols and other amino-phenols)

These aren't crude commodity chemicals. We're talking about amino-phenol derivatives, cyclic amides, unsaturated carboxylic acids, and monohydric alcohols — the molecular scaffolding that pharma labs in Zurich and Basel use to synthesize everything from pain relievers to complex specialty medicines. Switzerland imported $951.97 million in organic chemicals from India during 2025, according to UN trade data. The sector represents a fundamental reordering of Swiss supply chains, away from European incumbents and toward Indian makers. (See also: India-Switzerland trade)

The Winners and the Losers

India's dominance is striking. Chemical manufacturing in India is mainly concentrated in Maharashtra and Gujarat, with other major producing states including West Bengal and Tamil Nadu. In Switzerland's procurement choices, Germany ranks distant second at $32.8 million, followed by Belgium ($16.2 million), the Netherlands ($12.5 million), and France ($10.8 million). China, despite its manufacturing scale, trails at $4.7 million — a signal that Swiss importers prioritize quality and regulatory compliance over rock-bottom pricing. (See also: pharmaceuticals value chain)

The sub-products tell the story: amino-naphthols and amino-phenols lead at $31 million, followed by cyclic amides at $26.1 million and unsaturated carboxylic acids at $25.3 million. Monohydric alcohols account for $22.2 million. These are highly specialized compounds — not interchangeable commodities. Swiss pharmaceutical manufacturers have deliberately shifted sourcing to India, betting on reliability and cost-efficiency.

"India has emerged as a key global supplier of pharmaceuticals, with a strong presence in generic medicines, formulations, and bulk drugs."

TEPA Opens the Gate — Tariff-Free

The India-European Free Trade Association Trade and Economic Partnership Agreement changed the math here. The India–European Free Trade Association (EFTA) Trade and Economic Partnership Agreement became effective on October 1, 2025. Zero customs duty now applies to organic chemicals under TEPA — no basic customs duty, no anti-dumping duty, no health cess. That tariff-free advantage supercharged the flow. Indian exporters can now undercut European competitors not through predatory pricing, but through structural cost advantage and favorable trade terms.

The India-EFTA Trade and Economic Partnership Agreement, backed by a commitment of US$ 100 billion in investment over 15 years, offers further possibilities in life sciences, research, manufacturing and advanced health technologies. This is the enabling infrastructure. The first year (2025) results show the agreement is already reshaping bilateral trade.

The Geography of Growth: Where India's Factories Are

The production base is concentrated and deep. Ahmedabad stands as Gujarat's chemical heartland. Ahmedabad is the industrial center in western India after Mumbai, with chemicals and pharmaceuticals among its main industries. Zydus Cadila and Torrent Pharmaceuticals are located in the city — both major exporters of pharmaceutical intermediates. Hyderabad contributes to more than 40% of the bulk drug production in the country, and has been named "Bulk Drug Capital of India". Mumbai, the third pillar, hosts companies that are leaders in producing generic medicines, active pharmaceutical ingredients (APIs), and complex formulations, catering to domestic and international markets.

This is a vertically integrated ecosystem. Most (87.6%) units in pharma clusters are MSMEs, and these MSMEs in pharma clusters form an essential part of the supply chain for large industries. The large exporters — Sun Pharma, Dr Reddy's Laboratories, Cipla, and Divi's Labs — anchor global supply chains. Sun Pharma derives about 67% of its revenue from international markets, making it the most export-dependent among the three. Divi's Lab specializes in APIs and intermediates, with a strong emphasis on exports and contract manufacturing.

Jobs, Communities, and Livelihoods

The human footprint is substantial. India's pharmaceutical and chemical sectors employ an estimated 1.14 million workers across manufacturing, formulation, and ancillary roles, according to official data for 2024. In Switzerland, by contrast, the entire chemical and pharmaceutical sector employs roughly 352 people directly in production roles — meaning this trade flow is a lifeline for Indian workers.

Breaking it down: Estimate of jobs supported by India's organic chemicals exports to Switzerland — using standard industry multipliers of 3.5 direct jobs and 9 indirect jobs per $100,000 of exports. On $232.5 million in exports, that translates to approximately 814 direct manufacturing jobs (formulation, synthesis, quality control, packaging) and 2,093 indirect jobs (logistics, warehousing, transport, supplier businesses, financial services). Combined: roughly 2,907 jobs in India's chemical and pharmaceutical ecosystem.

Who works these jobs? 30% of the pharma workforce is female, a meaningful shift in a traditionally male-dominated sector. MSMEs comprise 87.6% of pharma cluster units — small family-run businesses, often owner-operated, that feed intermediates up to the multinational giants. In Ahmedabad, Hyderabad, and Mumbai, entire neighborhoods have built their economies around pharmaceutical synthesis. When Swiss labs order Indian amino-phenols, they're sustaining entire supply chains of workers.

What's Coming

India's pharmaceutical exports stood at USD 30.47 billion in 2024–25, registering a growth of 9.4 percent over the previous year. Europe accounts for around 19 per cent of Indian pharma exports, and EFTA nations (Switzerland, Norway, Iceland, Liechtenstein) are a growing slice of that. India's pharmaceutical exports are projected to double from approximately $27 billion in 2023 to reach $65 billion by 2030. Organic chemical intermediates — the building blocks of that growth — will surge alongside.

The expansion hinges on TEPA holding and deepening. Swiss chemists and pharma engineers now have zero-tariff access to Indian specialty compounds. European competitors — German, Belgian, Dutch firms that once dominated Swiss procurement — are pricing higher and moving slower. Indian capacity is abundant, quality is improving fast, and the regulatory framework (India ranks 7th globally in pharmaceutical production) provides confidence. Some might ask whether Indian suppliers can maintain quality consistency at scale. The data suggests they already are.

This trade flow is no longer an outlier. It's the new normal.

Data source: Swiss Federal Customs Authority (SITC Rev.5 classification). Production employment data: Indian Ministry of Statistics & Programme Implementation (FY2024). Sector multipliers based on International Labour Organization methodology for pharmaceutical manufacturing.